BioMS Medical expands multiple sclerosis trial into The Netherlands

By Elaine Rigoli

Tampa, Fla., June 22 - BioMS Medical Corp. has received approval to start enrolling patients in The Netherlands for its pivotal phase 2/ 3 clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis.

Approval was received from the Competent Authority in The Netherlands, CCMO (Central Committee on Research Involving Human Subjects).

BioMS Medical said it is enrolling patients across Canada, the United Kingdom, Sweden and Denmark in its trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis.

The trial is a randomized, double-blind study enrolling about 553 patients who will be administered either MBP8298 or a placebo intravenously every six months for two years.

The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes.

BioMS Medical is a biotechnology company located in Edmonton, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.